PART I . Business Overview We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potent...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001104659-26-023167 | EDGAR | 73K words |
| 2025-03-13 | 2024-12-31 | 0001410578-25-000329 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0001410578-24-000307 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001410578-23-000224 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001410578-22-000436 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001104659-21-030445 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001104659-20-030742 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001144204-19-009973 | EDGAR | — |
| 2018-03-21 | 2017-12-31 | 0001144204-18-016175 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001144204-17-014611 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-110827 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001778 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001410578-25-001205 | EDGAR | — |
| 2024-11-18 | 2024-09-30 | 0001410578-24-002012 | EDGAR | — |
| 2024-10-29 | 2024-06-30 | 0001410578-24-001708 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001410578-24-000771 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002341 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001833 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001410578-23-000875 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001410578-22-002920 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0001410578-22-002052 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001410578-22-001231 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-04 | 0001104659-26-023169 | EDGAR | 3K words |
| 2025-11-13 | 0001104659-25-110848 | EDGAR | — |
| 2025-10-10 | 0001104659-25-098725 | EDGAR | — |
| 2025-10-06 | 0001104659-25-096928 | EDGAR | — |
| 2025-08-14 | 0001104659-25-078102 | EDGAR | — |
| 2025-06-26 | 0001104659-25-062837 | EDGAR | — |
| 2025-06-25 | 0001104659-25-062639 | EDGAR | — |
| 2025-06-18 | 0001104659-25-060661 | EDGAR | — |
| 2025-06-13 | 0001104659-25-059400 | EDGAR | — |
| 2025-06-05 | 0001104659-25-056697 | EDGAR | — |
513 total filings indexed. 481 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001279704 |
| Ticker | CLRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cellectar.com |
| Listed | 2005-04-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report